- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.07. | HCW Biologics Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 01.07. | HCW Biologics meldet vollständige Ausübung von vorfinanzierten Optionsscheinen durch Armistice Capital | 7 | Investing.com Deutsch | ||
| 01.07. | HCW Biologics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| HCW BIOLOGICS Aktie jetzt für 0€ handeln | |||||
| 27.06. | HCW Biologics entwickelt neue T-Zell-Engager für Bauchspeicheldrüsenkrebs | 1 | Investing.com Deutsch | ||
| 27.06. | HCW Biologics develops new T-cell engagers for pancreatic cancer | 1 | Investing.com | ||
| 27.06. | HCW Biologics Inc.: HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid Tumors | 1 | GlobeNewswire (USA) | ||
| 26.06. | HCW Biologics regains compliance with Nasdaq Capital Market requirements | 1 | Seeking Alpha | ||
| 26.06. | HCW Biologics erfüllt wieder alle Nasdaq-Notierungsanforderungen | 1 | Investing.com Deutsch | ||
| 26.06. | HCW Biologics Inc.: HCW Biologics Regains Compliance with Nasdaq Capital Market Requirements | 140 | GlobeNewswire (Europe) | MIRAMAR, Fla., June 26, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. ("HCWB" or the "Company") (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing... ► Artikel lesen | |
| 23.06. | HCW Biologics Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 13.06. | HCW Biologics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.06. | HCW Biologics Sinks on Alliance with WY Biotech | - | Baystreet.ca | ||
| 04.06. | HCW Biologics geht Partnerschaft mit WY Biotech für Immuntherapie ein | 1 | Investing.com Deutsch | ||
| 04.06. | HCW Biologics Inc.: HCW Biologics Completes Deliverable and Solidifies License Agreement with WY Biotech | 3 | GlobeNewswire (USA) | ||
| 30.05. | HCW Biologics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 23.05. | HCW Biologics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.05. | HCW Biologics GAAP EPS of -$0.05, revenue of $5.1K | 1 | Seeking Alpha | ||
| 16.05. | HCW Biologics GAAP EPS of -$0.20, revenue of $1.1M | 3 | Seeking Alpha | ||
| 16.05. | HCW Biologics clings on with $5M lifeline to fund phase 1 alopecia trial | 1 | FierceBiotech | ||
| 16.05. | HCW Biologics Inc.: HCW Biologics Reports First Quarter 2025 Business Highlights and Financial Results | 151 | GlobeNewswire (Europe) | MIRAMAR, Fla., May 15, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing... ► Artikel lesen |
1 2 3 Weiter >>
48 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | 0,240 | -14,59 % | Palatin Technologies, Inc.: Palatin Announces Positive Preclinical Efficacy Data for Oral MC4R Agonist PL7737 in Animal Model of Obesity | Oral PL7737 monotherapy produced rapid and significant weight loss after just 4 days of treatment
Combination of oral PL7737 and tirzepatide resulted in additive... ► Artikel lesen | |
| BIOXXMED | 0,250 | 0,00 % | EQS-News: bioXXmed AG informiert über die Verzögerung der Veröffentlichung des geprüften Jahresabschlusses 2024 | EQS-News: bioXXmed AG
/ Schlagwort(e): Jahresbericht
bioXXmed AG informiert über die Verzögerung der Veröffentlichung des geprüften Jahresabschlusses 2024
27.06.2025 /... ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market | SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development.... ► Artikel lesen | |
| OCUGEN | 0,829 | +0,68 % | Ocugen Provides Business Update with Second Quarter 2025 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Initiated dosing in OCU410ST Phase 2/3 GARDian3 pivotal confirmatory clinical trialActively dosing patients in OCU400 Phase 3 liMeliGhT clinical trial... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem Corp.: Sirona Biochem Update to Shareholders on Financial Status and Operations | VANCOUVER, British Columbia, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) ("Sirona") wishes to provide shareholders with a critical update on the company's financial... ► Artikel lesen | |
| BIO-GATE | 0,900 | -5,26 % | EQS-News: Bio-Gate AG: Bio-Gate veröffentlicht endgültige Zahlen 2024 und gibt positiven Ausblick für 2025 | EQS-News: Bio-Gate AG
/ Schlagwort(e): Jahresergebnis
Bio-Gate veröffentlicht endgültige Zahlen 2024 und gibt positiven Ausblick für 2025
31.07.2025 / 21:17 CET/CEST
Für... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,371 | -4,13 % | Defence Therapeutics Inc.: Defence's Accum Technology with ADC and Radiopharmaceutical Programs Target Cancer | Montreal, Quebec--(Newsfile Corp. - July 14, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug... ► Artikel lesen | |
| VAXART | 0,278 | -13,25 % | Vaxart, Inc. - 8-K, Current Report | ||
| BURCON NUTRASCIENCE | 1,840 | 0,00 % | Burcon NutraScience Corporation: Burcon Achieves First Commercial Production of Fava Protein and Officially Launches FavaPro 90%+ Pure Plant Protein | Vancouver, British Columbia--(Newsfile Corp. - August 5, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in plant-based protein... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 4,930 | 0,00 % | Cellectar Biosciences, Inc.: Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement | Partnership Provides Long-Term Supply of Iodine-125 and Actinium-225 Supports Advancement of Radiotherapeutic Pipeline and Plans to Initiate Phase 1b Clinical Trial of CLR-125 for Triple-Negative... ► Artikel lesen | |
| AFFIMED | 0,972 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 28.05.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 28.05.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 28.05.2025ISIN NameBMG3728V1090 GAN... ► Artikel lesen | |
| AIM IMMUNOTECH | 0,073 | -100,00 % | AIM ImmunoTech Inc.: AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen Clinical Development Toward Pancreatic Cancer Approval | Primary focus on pancreatic cancer Mid-year report of Ampligen® (rintatolimod) in combination with AstraZeneca's Imfinzi® (durvalumab) for the treatment of pancreatic cancer demonstrates positive... ► Artikel lesen | |
| IMMUNIC | 0,895 | +5,29 % | EQS-News: Immunic AG: Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis | Issuer: Immunic AG
/ Key word(s): Study/Study results
Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in... ► Artikel lesen | |
| T2 BIOSYSTEMS | 0,124 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 20.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 20.02.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 20.02.2025.ISIN NameCA24703H1029 DELIVRA... ► Artikel lesen | |
| CEL-SCI | 8,790 | 0,00 % | CEL-SCI Corporation: CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer | Strong interest from Saudi investment funds in CEL-SCI, Multikine, and potential joint venture to address the wider Middle East and North Africa market Patient access and reimbursement/sale in... ► Artikel lesen |
Das Unternehmen HCW BIOLOGICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 4,195 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HCW BIOLOGICS INC finden Sie auf Wallstreet Online.